NewAmsterdam Pharma (NAMS) Profit After Tax (2023 - 2026)
NewAmsterdam Pharma (NAMS) reported Profit After Tax of -$48.4 million for Q1 2026, down 22.45% on a YoY basis from -$62.5 million in Q1 2025, and up 35.35% sequentially from -$74.9 million in Q4 2025.
NewAmsterdam Pharma (NAMS) Profit After Tax (2023 - 2026) Analysis & Trends
NewAmsterdam Pharma (NAMS) has 4 years of Profit After Tax data on file, last reported at -$48.4 million in Q1 2026.
- For the quarter ending Q1 2026, Profit After Tax fell 22.45% year-over-year to -$48.4 million; the trailing twelve-month figure through Mar 2026 stood at -$212.8 million (down 13.58% YoY), and the FY2025 full-year result was -$203.8 million, up 15.64% from the prior year.
- Profit After Tax grew to -$48.4 million in Q1 2026, from -$74.9 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$16.6 million in Q3 2024 to a low of -$93.8 million in Q1 2024.
- A 4-year average of -$51.6 million and a median of -$47.1 million in 2023 frame the typical range for Profit After Tax.
- Across the five-year window, Profit After Tax soared 64.68% in 2024 and sank 332.54% in 2025, its largest moves.
- Tracing NAMS's Profit After Tax over 4 years: stood at -$49.5 million in 2023, then slumped by 86.23% to -$92.2 million in 2024, then climbed by 18.72% to -$74.9 million in 2025, then surged by 35.35% to -$48.4 million in 2026.
- Business Quant data shows NAMS's Profit After Tax at -$48.4 million in Q1 2026, -$74.9 million in Q4 2025, and -$72.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | NewAmsterdam Pharma | 3.64 Bn | 3.64 Bn | - | -48.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -48.44 Mn |
| Dec 31, 2025 | -74.92 Mn |
| Sep 30, 2025 | -72.01 Mn |
| Jun 30, 2025 | -17.47 Mn |
| Mar 31, 2025 | -39.56 Mn |
| Dec 31, 2024 | -92.18 Mn |
| Sep 30, 2024 | -16.65 Mn |
| Jun 30, 2024 | -39.01 Mn |
| Mar 31, 2024 | -93.77 Mn |
| Dec 31, 2023 | -49.50 Mn |
| Sep 30, 2023 | -47.13 Mn |
| Jun 30, 2023 | -38.29 Mn |
| Mar 31, 2023 | -42.02 Mn |